Insider Selling: Phreesia, Inc. (NYSE:PHR) SVP Sells 11,616 Shares of Stock

Phreesia, Inc. (NYSE:PHR) SVP David Linetsky sold 11,616 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $29.70, for a total value of $344,995.20. Following the completion of the transaction, the senior vice president now directly owns 218,135 shares in the company, valued at $6,478,609.50. This trade represents a 5.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David Linetsky also recently made the following trade(s):

• On Friday, February 7th, David Linetsky sold 300 shares of Phreesia stock. The shares were sold at an average price of $29.52, for a total value of $8,856.00.
• On Wednesday, February 5th, David Linetsky sold 720 shares of Phreesia stock. The stock was sold at an average price of $29.50, for a total value of $21,240.00.
• On Wednesday, January 29th, David Linetsky sold 500 shares of Phreesia stock. The stock was sold at an average price of $29.68, for a total value of $14,840.00.
• On Monday, January 27th, David Linetsky sold 11,685 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total value of $321,103.80.
• On Wednesday, December 18th, David Linetsky sold 24 shares of Phreesia stock. The stock was sold at an average price of $25.38, for a total value of $609.12.
• On Monday, December 16th, David Linetsky sold 35 shares of Phreesia stock. The stock was sold at an average price of $24.88, for a total value of $870.80.
• On Wednesday, December 11th, David Linetsky sold 11,853 shares of Phreesia stock. The stock was sold at an average price of $24.85, for a total value of $294,547.05.

Phreesia Stock Performance

Shares of NYSE:PHR traded up $0.15 during trading on Tuesday, hitting $29.99. 409,526 shares of the company traded hands, compared to its average volume of 382,504. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -20.40 and a beta of 0.96. The business’s fifty day moving average is $26.93 and its 200-day moving average is $23.68. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.04.

Phreesia (NYSE:PHR) last posted its earnings results on Monday, December 9th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million during the quarter, compared to analyst estimates of $106.33 million. During the same period in the prior year, the company earned ($0.58) earnings per share. The business’s revenue was up 16.6% compared to the same quarter last year. As a group, equities analysts predict that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. KeyCorp lifted their target price on Phreesia from $28.00 to $30.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 8th. Needham & Company LLC restated a “buy” rating and set a $29.00 price objective on shares of Phreesia in a research note on Friday, January 10th. JMP Securities restated a “market outperform” rating and set a $30.00 price objective on shares of Phreesia in a research note on Tuesday, December 10th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and upped their price objective for the company from $24.00 to $32.00 in a research note on Wednesday, January 8th. Finally, Robert W. Baird cut their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 11th. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia has an average rating of “Buy” and an average target price of $31.15.

Hedge Funds Weigh In On Phreesia

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Phreesia by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 4,823,110 shares of the company’s stock worth $121,349,000 after buying an additional 61,048 shares in the last quarter. Greenhouse Funds LLLP boosted its stake in Phreesia by 27.9% during the 4th quarter. Greenhouse Funds LLLP now owns 2,873,892 shares of the company’s stock valued at $72,307,000 after purchasing an additional 626,579 shares in the last quarter. Champlain Investment Partners LLC boosted its stake in Phreesia by 4.1% during the 3rd quarter. Champlain Investment Partners LLC now owns 2,503,837 shares of the company’s stock valued at $57,062,000 after purchasing an additional 97,847 shares in the last quarter. Franklin Resources Inc. boosted its stake in Phreesia by 0.8% during the 4th quarter. Franklin Resources Inc. now owns 1,509,617 shares of the company’s stock valued at $37,982,000 after purchasing an additional 11,986 shares in the last quarter. Finally, State Street Corp boosted its stake in Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock valued at $30,256,000 after purchasing an additional 88,517 shares in the last quarter. 92.10% of the stock is owned by institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.